Journal of Allergy and Clinical Immunology

Article	Citations
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan	1496
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19	740
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19	522
2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group	427
Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2	423
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials	383
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial	344
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19	279
Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis	269
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study	264
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells	254
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia	251
Eosinophil responses during COVID-19 infections and coronavirus vaccination	244
Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China	238
Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19	229
Type I IFN immunoprofiling in COVID-19 patients	215
Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study	207
Complement activation in patients with COVID-19: A novel therapeutic target	202
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection	184
COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience	181
Influence of immune aging on vaccine responses	180
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management	178
Epithelial barriers in allergy and asthma	176
Environmental factors in epithelial barrier dysfunction	175
Association of asthma and its genetic predisposition with the risk of severe COVID-19	163

IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study	158
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council	153
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity	150
Drug allergy: A 2022 practice parameter update	149
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial	149
Rhinitis 2020: A practice parameter update	148
IL-6–based mortality risk model for hospitalized patients with COVID-19	146
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial	145
Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1	139
JAK inhibitors in the treatment of atopic dermatitis	135
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19	131
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study	123
Food allergy across the globe	121
Air pollution, racial disparities, and COVID-19 mortality	121
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines	117
Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type–specific immune regulation in atopic dermatitis	117
New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation	116
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis	114
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease	109
Asthma-associated risk for COVID-19 development	108
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon	108
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial	107
Asthma among hospitalized patients with COVID-19 and related outcomes	105
The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease	105
Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS	102
Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses	102
Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score	101
Biomarkers of severity and threshold of allergic reactions during oral peanut challenges	100
Obesity and asthma	98
Cutaneous barrier dysfunction in allergic diseases	97
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis	94
Regulating T-cell differentiation through the polyamine spermidine	94
COVID-19: Unanswered questions on immune response and pathogenesis	90
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)	90
Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1	89
Staphylococcus epidermidis protease EcpA can be a deleterious component of the skin microbiome in atopic dermatitis	88
Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach	87
Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype	86
Randomized trial of early infant formula introduction to prevent cow’s milk allergy	86
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study	83
Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction	83
Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: A Work Group Report of the AAAAI Committee on the Underserved	83
SARS-CoV-2 antibody testing—questions to be asked	82
Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)	82
Mechanisms and pathogenesis of chronic rhinosinusitis	81
Autoimmune chronic spontaneous urticaria	81
Clinical testing for COVID-19	80
COVID-19–associated multisystem inflammatory syndrome in children (MIS-C): A novel disease that mimics toxic shock syndrome—the superantigen hypothesis	80
Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8+ T cells in autoimmunity and cancer	78
Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies	77

Climate change and global issues in allergy and immunology	77
Type 2 inflammation in chronic rhinosinusitis without nasal polyps: Another relevant endotype	76
Basophil reactivity to BNT162b2 is mediated by PEGylated lipid nanoparticles in patients with PEG allergy	76
The role of neutrophils in host defense and disease	75
The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults	74
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trial	74
Atopic dermatitis displays stable and dynamic skin transcriptome signatures	74
Subepidermal blistering eruptions, including bullous pemphigoid, following COVID-19 vaccination	74
Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations	74
IL-25 (IL-17E) in epithelial immunology and pathophysiology	73
Initial presenting manifestations in 16,486 patients with inborn errors of immunity include infections and noninfectious manifestations	72
Severity grading system for acute allergic reactions: A multidisciplinary Delphi study	71
The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases	70
Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity	70
ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma—implications for COVID-19	70
Multifaceted MRGPRX2: New insight into the role of mast cells in health and disease	70
Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention	70
Compartmental immunophenotyping in COVID-19 ARDS: A case series	69
Advances in asthma: New understandings of asthma’s natural history, risk factors, underlying mechanisms, and clinical management	69
The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular	69
Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results	69
Mas-related G protein–coupled receptor X2 and its activators in dermatologic allergies	69
A substantial neutrophilic inflammation as regular part of severe type 2 chronic rhinosinusitis with nasal polyps	68
ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation	66
Phase 2 randomized, double-blind study of IL-17 targeting with secukinumab in atopic dermatitis	66
Mechanisms and biomarkers of inflammatory endotypes in chronic rhinosinusitis without nasal polyps	63
Mild atopic dermatitis lacks systemic inflammation and shows reduced nonlesional skin abnormalities	63
Single-cell transcriptomics applied to emigrating cells from psoriasis elucidate pathogenic versus regulatory immune cell subsets	63
Therapeutic options for CTLA-4 insufficiency	63
SCID newborn screening: What we’ve learned	63
Glucocorticoids and the cytokines IL-12, IL-15, and IL-18 present in the tumor microenvironment induce PD-1 expression on human natural killer cells	63
Rethinking neutrophils and eosinophils in chronic rhinosinusitis	63
Ara h 2 is the dominant peanut allergen despite similarities with Ara h 6	63
Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results	62
Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers	61
JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition	61
Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa	61
The role of eosinophils in chronic spontaneous urticaria	61
Cow’s milk protein β-lactoglobulin confers resilience against allergy by targeting complexed iron into immune cells	61
Novel hereditary angioedema linked with a heparan sulfate 3-O-sulfotransferase 6 gene mutation	60
Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study	60
Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy	59
Chemokines and eicosanoids fuel the hyperinflammation within the lungs of patients with severe COVID-19	59
Efficacy of early anti-inflammatory treatment with high doses of intravenous anakinra with or without glucocorticoids in patients with severe COVID-19 pneumonia	59
Incidence of cancer after asthma development: 2 independent population-based cohort studies	58
Developmental patterns in the nasopharyngeal microbiome during infancy are associated with asthma risk	58
Peanut allergy diagnosis: A 2020 practice parameter update, systematic review, and GRADE analysis	58
COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: Nationwide real-world evidence	58
Nasal DNA methylation profiling of asthma and rhinitis	57
Successful use of methylprednisolone for treating severe COVID-19	57
Accuracy of penicillin allergy diagnostic tests: A systematic review and meta-analysis	57
IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease	57
The HOME Core outcome set for clinical trials of atopic dermatitis	56
Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees	56
Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort	55
Global patterns in anaphylaxis due to specific foods: A systematic review	55
Non–IgE-mediated anaphylaxis	55
The maternal gut microbiome during pregnancy and offspring allergy and asthma	54
CD4+ and CD8+ cytotoxic T lymphocytes may induce mesenchymal cell apoptosis in IgG4-related disease	54
SARS-CoV-2 infection and viral load are associated with the upper respiratory tract microbiome	54
Single-cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis	53
Association of frequent moisturizer use in early infancy with the development of food allergy	53
Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations	53
Genetic analyses identify GSDMB associated with asthma severity, exacerbations, and antiviral pathways	53
Molecular profiling of allergen-specific antibody responses may enhance success of specific immunotherapy	53
Induction of sustained unresponsiveness after egg oral immunotherapy compared to baked egg therapy in children with egg allergy	53
Urbanized microbiota in infants, immune constitution, and later risk of atopic diseases	53
Air pollution and lung function in children	52
Animal models of psoriasis—highlights and drawbacks	52
Treatment of chronic or relapsing COVID-19 in immunodeficiency	52
Age and eczema severity, but not family history, are major risk factors for peanut allergy in infancy	52
Can blocking inflammation enhance immunity during aging?	51
Optimizing investigation of suspected allergy to polyethylene glycols	51
Diverse immune mechanisms of allergen immunotherapy for allergic rhinitis with and without asthma	51
Long-term follow-up of 168 patients with X-linked agammaglobulinemia reveals increased morbidity and mortality	51
Mutual regulation of metabolic processes and proinflammatory NF-κB signaling	51
CD4+ T-cell differentiation and function: Unifying glycolysis, fatty acid oxidation, polyamines NAD mitochondria	50
Investigating asthma heterogeneity through shared and distinct genetics: Insights from genome-wide cross-trait analysis	50
Distinct associations of sputum and oral microbiota with atopic, immunologic, and clinical features in mild asthma	49
A 300 IR sublingual tablet is an effective, safe treatment for house dust mite–induced allergic rhinitis: An international, double-blind, placebo-controlled, randomized phase III clinical trial	49

Dietary fiber and SCFAs in the regulation of mucosal immunity	49
Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12 to 18 months	49
An open-label, proof-of-concept study of lirentelimab for antihistamine-resistant chronic spontaneous and inducible urticaria	49
Neuroimmune communication regulating pruritus in atopic dermatitis	48
Distinct cytokine profiles associated with COVID-19 severity and mortality	48
Remibrutinib, a novel BTK inhibitor, demonstrates promising efficacy and safety in chronic spontaneous urticaria	48
Allergen-specific IgG+ memory B cells are temporally linked to IgE memory responses	48
Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians	47
Structural racism and its pathways to asthma and atopic dermatitis	47
Airway smooth muscle pathophysiology in asthma	47
Integrated-omics endotyping of infants with rhinovirus bronchiolitis and risk of childhood asthma	46
Consensus report from the Food Allergy Research & Education (FARE) 2019 Oral Immunotherapy for Food Allergy Summit	46
Early-life exposure to submicron particulate air pollution in relation to asthma development in Chinese preschool children	46
Persistent, refractory, and biphasic anaphylaxis: A multidisciplinary Delphi study	46
COVID-19 risk stratification algorithms based on sTREM-1 and IL-6 in emergency department	46
IgG Fc sialylation is regulated during the germinal center reaction following immunization with different adjuvants	45
Risk factors for hospitalization, intensive care, and mortality among patients with asthma and COVID-19	45
Gut microbiota development during infancy: Impact of introducing allergenic foods	45
IL-33 signaling in sensory neurons promotes dry skin itch	45
Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies	45
The importance of the 2S albumins for allergenicity and cross-reactivity of peanuts, tree nuts, and sesame seeds	45
A novel STING1 variant causes a recessive form of STING-associated vasculopathy with onset in infancy (SAVI)	45
Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis	44
Mepolizumab for chronic rhinosinusitis with nasal polyps: Treatment efficacy by comorbidity and blood eosinophil count	44
Prognostic factors for polyp recurrence in chronic rhinosinusitis with nasal polyps	44
Immunophenotyping in pemphigus reveals a TH17/TFH17 cell–dominated immune response promoting desmoglein1/3-specific autoantibody production	44
Roles of innate lymphoid cells (ILCs) in allergic diseases: The 10-year anniversary for ILC2s	44
The epithelial barrier hypothesis proposes a comprehensive understanding of the origins of allergic and other chronic noncommunicable diseases	43
Hereditary alpha tryptasemia is not associated with specific clinical phenotypes	43
Regulating metabolic inflammation by nutritional modulation	43
Hsa_circ_0004287 inhibits macrophage-mediated inflammation in an N6-methyladenosine–dependent manner in atopic dermatitis and psoriasis	43
The immunologic status of newborns born to SARS-CoV-2–infected mothers in Wuhan, China	43
Multisystem inflammation and susceptibility to viral infections in human ZNFX1 deficiency	43
Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remission	43
Highways to hell: Mechanism-based management of cytokine storm syndromes	42
Mechanisms of skin autoimmunity: Cellular and soluble immune components of the skin	42
Reframing racial and ethnic disparities in atopic dermatitis in Black and Latinx populations	42
lnc-BAZ2B promotes M2 macrophage activation and inflammation in children with asthma through stabilizing BAZ2B pre-mRNA	42
Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective	42
Transcriptomic characterization of prurigo nodularis and the therapeutic response to nemolizumab	42
Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS)	42
Uniting biobank resources reveals novel genetic pathways modulating susceptibility for atopic dermatitis	42
C5aR inhibition of nonimmune cells suppresses inflammation and maintains epithelial integrity in SARS-CoV-2–infected primary human airway epithelia	41
Activation of the 15-lipoxygenase pathway in aspirin-exacerbated respiratory disease	41
Use of multiple epinephrine doses in anaphylaxis: A systematic review and meta-analysis	41
Immunologic memory to SARS-CoV-2 in convalescent COVID-19 patients at 1 year postinfection	41
Dual function of Langerhans cells in skin TSLP-promoted TFH differentiation in mouse atopic dermatitis	41
Treatment of severe lichen planus with the JAK inhibitor tofacitinib	41
JAK inhibitors for asthma	40
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity	40
Dissecting the complexity of γδ T-cell subsets in skin homeostasis, inflammation, and malignancy	40
CaMKII oxidation regulates cockroach allergen–induced mitophagy in asthma	40
Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis	40
Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency	40
Esophageal type 2 cytokine expression heterogeneity in eosinophilic esophagitis in a multisite cohort	40
Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis	40
Midostaurin improves quality of life and mediator-related symptoms in advanced systemic mastocytosis	40
Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects	40
The natural history of peanut and egg allergy in children up to age 6 years in the HealthNuts population-based longitudinal study	40
Principles, potential, and limitations of ex vivo basophil activation by flow cytometry in allergology: A narrative review	39
Type 2–high asthma is associated with a specific indoor mycobiome and microbiome	39
Current insights into the genetics of food allergy	39
Does asthma affect morbidity or severity of COVID-19?	39
Housing and asthma disparities	39
Novel insights into the TRPV3-mediated itch in atopic dermatitis	39
Dissecting the mechanism of action of intravenous immunoglobulin in human autoimmune disease: Lessons from therapeutic modalities targeting Fcγ receptors	39
Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience	39
Differential induction of allergen-specific IgA responses following timothy grass subcutaneous and sublingual immunotherapy	39
Ara h 2–specific IgE is superior to whole peanut extract–based serology or skin prick test for diagnosis of peanut allergy in infancy	39
Asthmatic patients in COVID-19 outbreak: Few cases despite many cases	39
Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study	38
The microbial origins of food allergy	38
IL-10 production by ILC2s requires Blimp-1 and cMaf, modulates cellular metabolism, and ameliorates airway hyperreactivity	38
FcεR1-expressing nociceptors trigger allergic airway inflammation	38
Phenotype and risk factors of venom-induced anaphylaxis: A case-control study of the European Anaphylaxis Registry	38
Using data from food challenges to inform management of consumers with food allergy: A systematic review with individual participant data meta-analysis	37
Cardiovascular changes during peanut-induced allergic reactions in human subjects	37
Belinostat resolves skin barrier defects in atopic dermatitis by targeting the dysregulated miR-335:SOX6 axis	37
Ceramide in apoptosis and oxidative stress in allergic inflammation and asthma	37
Prevention and management of allergic reactions to food in child care centers and schools: Practice guidelines	37
Mepolizumab targets multiple immune cells in aspirin-exacerbated respiratory disease	37
Inflammatory heterogeneity in aspirin-exacerbated respiratory disease	37
Asivatrep, a TRPV1 antagonist, for the topical treatment of atopic dermatitis: Phase 3, randomized, vehicle-controlled study (CAPTAIN-AD)	37
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers	37
Excessive deubiquitination of NLRP3-R779C variant contributes to very-early-onset inflammatory bowel disease development	36
Understanding the asthmatic response to an experimental rhinovirus infection: Exploring the effects of blocking IgE	36
Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis	36
Mechanisms of human drug-induced anaphylaxis	36
The airway as a route of sensitization to peanut: An update to the dual allergen exposure hypothesis	36
Treatment of granuloma annulare and suppression of proinflammatory cytokine activity with tofacitinib	36
Assessing the unified airway hypothesis in children via transcriptional profiling of the airway epithelium	36
Abnormality in the NK-cell population is prolonged in severe COVID-19 patients	36
Staphylococcus aureus second immunoglobulin-binding protein drives atopic dermatitis via IL-33	36
Eight novel susceptibility loci and putative causal variants in atopic dermatitis	36
Defining baseline variability of serum tryptase levels improves accuracy in identifying anaphylaxis	36